[
    [
        {
            "time": "2021-08-29",
            "original_text": "为何重组蛋白新冠疫苗保护率甚高？【东吴医药朱国广团队|0829周报】",
            "features": {
                "keywords": [
                    "重组蛋白",
                    "新冠疫苗",
                    "保护率",
                    "东吴医药",
                    "朱国广团队"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "为何重组蛋白新冠疫苗保护率甚高？【东吴医药朱国广团队|0829周报】",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]